Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study

University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.
University of Washington. Department of Global Health. Seattle, WA, USA
University of Washington. Laboratory Medicine. Seattle, WA, USA.
University of Washington. Department of Global Health. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
University of Washington. Laboratory Medicine. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.
University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.
University of the Witwatersrand. Faculty of Health Sciences. Department of Medicine. Clinical HIV Research Unit. Johannesburg, South Africa.
Fundação Oswaldo Cruz. Instituto de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Kamuzu Central Hospital. Lilongwe, Malawi.
Nelson R. Mandela School of Medicine. Durban, South Africa.
College of Medicine. Department of Medicine. Blantyre, Malawi.
Institut Nacional de laboratoire et de Recherches. Port-au-Prince, Haiti.
Asociación Civil Impacta Salud y Educación, Lima, Peru.
Grupo Hospitalar Conceição. Hospital Nossa Senhora da Conceição. Serviço de Infectology. Porto Alegre, RS, Brazil.
Chiang Mai University. Department of Medicine. Thailand / Chiang Mai University. Research Institute for Health Sciences. Thailand
University of Zimbabwe. College of Health Sciences, Harare.
YRG Centre for AIDS Research and Education, Chennai, India.
University of Colorado. School of Medicine. Department of Medicine. Aurora, CO, USA.

Resumo em Inglês

Objective. Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design. Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants. Methods. HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen. Results. Of 365 HSV-2–seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval, .55–1.44). Conclusions. HSV-2 acquisition was not reduced in HIVinfected, HSV-2–uninfected persons during TDF-containing ART.

Palavras-chave em inglês

HIV-1
HSV-2
Prevention
Tenofovir
Antiretroviral therapy
Africa

Editor

Elsevier

Referência

CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, Mar. 2017.

DOI

10.1093/infdis/jix029

ISSN

1413-8670

Notas

ACTG PEARLS/A5175 Team.

Use este identificador para citar ou linkar para este item: https://www.arca.fiocruz.br/handle/icict/34394

Tipo de documento

Direito Autoral

Acesso aberto

Coleções

Compartilhar

Estatísticas

Metadata

Autor(es)

Afiliação